Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11981498 | 0.90 | SMN1; SMN2 (0.50) | MEN1KMT2AHSD17B10SIGMAR1CASP2 | |
| SCHEMBL11538802 | 0.90 | MEN1 (0.44) | MEN1KMT2AHSD17B10SIGMAR1CASP2 | |
| SCHEMBL18784665 | 0.88 | GNAI3 (0.58) | MEN1KMT2AHSD17B10SIGMAR1CASP2 | |
| SCHEMBL18784666 | 0.88 | GNAI3 (0.58) | MEN1KMT2AHSD17B10SIGMAR1CASP2 | |
| SCHEMBL8572773 | 0.86 | MEN1 (0.56) | MEN1KMT2AHSD17B10SIGMAR1KDM4E | |
| SCHEMBL84809 | 0.84 | ALDH1A1 (0.55) | MEN1KMT2ACASP2KDM4EGAA | |
| SCHEMBL8408995 | 0.83 | HDAC2 (0.49) | CASP2KDM4EALDH1A1CYP2C19POLB | |
| SCHEMBL84807 | 0.83 | ALDH1A1 (0.58) | MEN1KMT2ACASP2KDM4EALDH1A1 | |
| SCHEMBL18381298 | 0.83 | KMT2A (0.50) | MEN1KMT2AHSD17B10SIGMAR1KDM4E | |
| SCHEMBL20124225 | 0.83 | GNAI3 (0.49) | MEN1KMT2AHSD17B10SIGMAR1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130279-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | NESTEC S.A. (CH) | 2016-05-12 | — | — | US | disclosed |
| US-8747904-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130266617-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130266617-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8287910-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8287910-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100292432-A1 | POLYMERS FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010127159-A2 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | NCL, POLN, CHMP4B | MEN1 677/4885KMT2A 2877/4885HSD17B10 4042/4885 |
| US-20130266617-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | NCL, POLN, CHMP4B | MEN1 677/4885KMT2A 2877/4885HSD17B10 4042/4885 |
| US-20160130279-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | FABP2, TPH2, TPH1 | MEN1 4331/4885KMT2A 3586/4885HSD17B10 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.